Jeffrey Dierks - Feb 28, 2022 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
Chief Commercial Officer
Signature
/s/ Christian Ulrich, Attorney-in-fact for Jeffrey Dierks
Stock symbol
HRMY
Transactions as of
Feb 28, 2022
Transactions value $
-$315,604
Form type
4
Date filed
3/2/2022, 03:05 PM
Previous filing
Feb 18, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $241K +10K $24.00 10K Feb 28, 2022 Direct
transaction HRMY Common Stock Sale -$402K -10K -100% $40.00 0 Feb 28, 2022 Direct F1, F2
transaction HRMY Common Stock Options Exercise $40K +4.87K $8.22* 4.87K Mar 1, 2022 Direct
transaction HRMY Common Stock Sale -$195K -4.87K -100% $40.04 0 Mar 1, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -10K -7.14% $0.00 131K Feb 28, 2022 Common Stock 10K $24.00 Direct F4
transaction HRMY Stock Option Options Exercise $0 -4.87K -25% $0.00 14.6K Mar 1, 2022 Common Stock 4.87K $8.22 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.06. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.74 to $40.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option vests in five equal annual installments beginning on August 21, 2021.
F5 The stock option vests in five equal annual installments beginning on March 4, 2021